Alnylam Pharmaceuticals Inc
ALNY
Market Cap$18.1B
Close$
$160.69
12.1% upside
Current Fair Value
12.1% upsideUndervalued by 12.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $18.10 Billion |
|---|---|
| Enterprise Value | $16.68 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-3.52 |
| Beta | 0.0 |
| Outstanding Shares | 125,945,793 |
| Avg 30 Day Volume | 501,220 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -41.11 |
|---|---|
| PEG | 122.53 |
| Price to Sales | 10.24 |
| Price to Book Ratio | -71.66 |
| Enterprise Value to Revenue | 9.12 |
| Enterprise Value to EBIT | -59.12 |
| Enterprise Value to Net Income | -38 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | -4.63 |
Revenue Sources
No data
ESG Score
No data
About Alnylam Pharmaceuticals Inc
CEO: John Maraganore